RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q4 2025 investor letter. A copy of the letter can be downloaded here. The US stock market delivered modest gains in the quarter with the S&P 500 index (“S&P”) and the Russell 1000 Growth index (“RLG”) returning 2.6% and 1.1%, respectively. The Fund appreciated by 1.4% during the same period. For the full year, the Fund was up 13.3% vs. 17.4% and 18.6% gains, respect ...

Core Viewpoint - Citi upgraded Intuitive Surgical to Buy, maintaining Buy ratings on Stryker and Abbott, citing strong fundamentals in the medical technology sector despite market volatility [1][2] Summary by Company Intuitive Surgical - Upgraded from Neutral to Buy with a new price target of $590, reflecting a strong double-digit growth trajectory despite a 14.2% year-to-date decline in stock price [1] - Q4 2025 revenue was $2.87 billion, up 18.76% year-over-year, with non-GAAP EPS of $2.53, exceeding estimates [1] - The da Vinci 5 platform saw 303 system placements in Q4, a significant increase from 174 in the same quarter the previous year [1][2] Stryker - Maintained Buy rating with a price target of $420, and a 90-day catalyst watch added to monitor near-term developments [1] - Achieved over $25 billion in annual revenue for the first time in 2025, with full-year revenue of $25.12 billion, up 11.16% [1] - Adjusted EPS guidance for 2026 is between $14.90 and $15.10, indicating a stable growth outlook [2] Abbott - Buy rating maintained, but price target lowered to $136 from $140, reflecting a modest growth profile [1] - Q4 revenue was $11.46 billion, a 4.42% year-over-year increase, with the medical devices segment showing growth [1] - The pending $21 billion acquisition of Exact Sciences is expected to enhance Abbott's long-term growth potential [1][2] Market Context - The VIX index surged to 25.50, indicating increased market volatility, which has compressed valuations across the medical technology sector [1] - Intuitive Surgical's stock trades at approximately 49x forward earnings, reflecting its growth rate and competitive position in robotic-assisted surgery [1] - Stryker's forward P/E is around 24x, while Abbott's is near 20x, indicating a more conservative valuation approach for income-oriented investors [2]

Core Viewpoint - Intuitive Surgical is facing challenges in the current market, but patient investors may find opportunities as the stock has recently dipped due to weak guidance for future growth [1][3]. Financial Performance - In Q4 2025, Intuitive Surgical reported a revenue increase of 19% year-over-year, reaching $2.87 billion, with a 17% rise in da Vinci procedure volume and earnings per share of $2.21, up 17.6% year-over-year [2]. - The company anticipates da Vinci procedure volume growth of 13% to 15% for fiscal 2026, a decrease from 18% in 2025, which is a critical factor for revenue growth [3]. Market Position and Valuation - Intuitive Surgical is currently trading at 54 times forward earnings, significantly higher than the healthcare sector average of 18.6, indicating that the stock is priced for perfection [4]. - The company has a market capitalization of $179 billion, with a current stock price of $504.22, and a gross margin of 70.56% [6]. Long-term Prospects - Despite potential short-term volatility, Intuitive Surgical is positioned well for long-term growth due to the underpenetrated robotic-assisted surgery market and demographic trends such as an aging population [6][9]. - The company benefits from high switching costs and significant barriers to entry, along with extensive real-world data supporting improved patient outcomes [7]. Valuation Considerations - When considering expected growth, Intuitive Surgical's price/earnings-to-growth multiple is 3.2, which, while above the typical reasonable range, is not excessively high given the company's competitive advantages [8].

Financial Performance - Intuitive Surgical reported revenue of $2.87 billion for the fourth quarter, exceeding analyst estimates of $2.75 billion [1] - The company reported adjusted earnings of $2.53 per share, surpassing analyst expectations of $2.26 per share [1] Future Expectations - Intuitive Surgical anticipates a 13% to 15% increase in worldwide da Vinci procedures for full-year 2026, a decrease from the 18% growth expected in 2025 [2] - The company expects gross profit margin to be between 67% and 68% of revenue in 2026, slightly down from 67.6% in 2025 [2] Stock Performance and Analyst Ratings - Following the earnings announcement, Intuitive Surgical shares increased by 0.2%, trading at $526.86 [2] - Bernstein analyst Lee Hambright maintained an Outperform rating and raised the price target from $740 to $750 [3] - Evercore ISI Group analyst Vijay Kumar maintained an In-Line rating and lowered the price target from $580 to $550 [3]

Summary of MicroPort MedBot Conference Call Company Overview - **Company**: MicroPort MedBot (Ticker: 2252.HK) - **Market Cap**: HK$31,889 million (US$4,089 million) [4] Key Industry Insights - **Industry**: Robotic-assisted surgery - **Policy Development**: On January 20, 2026, China's National Healthcare Security Administration (NHSA) introduced a unified national pricing framework for robotic surgery, which is expected to significantly impact the industry by resolving long-standing pricing uncertainties [2][3]. Core Financial Highlights - **Revenue Growth**: MicroPort MedBot anticipates a revenue increase of 110-120% year-over-year for FY25, surpassing previous estimates of 100% and consensus of 94% [1]. - **Net Loss Reduction**: The adjusted net loss is expected to narrow by more than 50%, aligning with market expectations [1]. - **Overseas Orders**: The company received over 100 orders for the Toumai robot in FY25, exceeding the previous guidance of 70-80 units [1]. Policy Impact - **Pricing Framework Features**: - **Tiered Pricing**: Establishes three tiers based on the robot's involvement in surgeries: Navigation, Partial Execution, and Precise Execution [2]. - **Coefficient-Based Reimbursement**: Links reimbursement for robotic assistance to the primary surgical procedure's price, incentivizing advanced robotics for complex surgeries [2]. - **Incentives**: Sets a price floor for manufacturers and a ceiling for patient affordability [2]. - **Remote Surgery**: Introduces a pricing item for remote surgical assistance, facilitating the commercialization of telesurgery [2]. Growth Drivers - **Dual-Engine Growth**: The company is expected to experience significant domestic adoption due to the new pricing framework, alongside continued strong international momentum [6]. - **Clinical Value**: The product's clinical value is validated with installations in over 90% of Grade-A Tertiary hospitals, indicating strong market acceptance [6]. Investment Outlook - **Rating**: The stock is rated as "Buy" with a target price of HK$32.00, reflecting an expected share price return of 3.5% [4]. - **Risk Assessment**: The stock is classified as high risk due to potential volatility and various operational risks, including regulatory challenges and competition [9]. Additional Considerations - **Market Reaction**: Following the announcement of the new pricing guideline, shares of MicroPort MedBot and its peers saw a positive market reaction, indicating investor confidence in the new policy's potential to de-risk commercialization pathways [1][3]. - **Visibility for Revenue Conversion**: The surge in overseas orders provides excellent visibility for revenue conversion in FY26, reinforcing the company's growth trajectory [1]. This summary encapsulates the key points from the conference call, highlighting the company's financial performance, industry developments, and future growth prospects.

Core Insights - Intuitive Surgical (ISRG) reported preliminary revenues for Q4 and full-year 2025, with Q4 revenues at $2.87 billion, a 19% increase year over year, surpassing the Zacks Consensus Estimate of $2.72 billion [1][10] - Full-year revenues are projected to be $10.06 billion, reflecting a 21% year-over-year growth, also exceeding the Zacks Consensus Estimate of $9.92 billion [5][10] Q4 Revenue Breakdown - Instruments and accessories revenues for Q4 are expected to be around $1.66 billion, marking a 17% increase from the previous year [2] - Preliminary systems revenues for Q4 are approximately $786 million, driven by increased da Vinci system placements and higher average selling prices [3] System Placements - ISRG placed 532 da Vinci Surgical systems in Q4 2025, up from 493 in the same period last year, with 250 of these under operating leases [4] Full-Year Performance - Instruments and accessories revenues for the full year are estimated at $6.02 billion, indicating a 19% growth year over year [5] - Systems revenues improved to $2.47 billion compared to 2024 [5] Growth Drivers - The strong performance in 2025 is attributed to higher adoption and utilization of surgical platforms, broader product clearances, and over 3.1 million da Vinci procedures completed during the year [6] - Procedure volumes have been increasing, particularly in U.S. general surgery and various specialties internationally, with expectations for a 13-15% growth in worldwide da Vinci procedures in 2026 [7] Competitive Positioning - The full launch of da Vinci 5 is enhancing system utilization and efficiency, supporting ISRG's leadership in robotic-assisted surgery [9] - The growing installed base contributes to a recurring revenue model, with significant revenues coming from recurring sources [9] Market Challenges - Despite strong performance, ISRG faces challenges such as pressure on gross margins due to tariffs and higher costs, as well as competition and pricing pressures in international markets like China, Japan, and the U.K. [11][12] - In the U.S., declining bariatric procedure volumes due to GLP-1 drugs present additional uncertainty [13]

Core Insights - Intuitive announced preliminary financial results for Q4 and full year 2025, highlighting significant revenue growth driven by increased procedure volume and system placements [1][3][10] Financial Performance - Q4 2025 revenue is expected to be approximately $2.87 billion, a 19% increase from $2.41 billion in Q4 2024 [3] - Full year 2025 revenue is projected at approximately $10.06 billion, reflecting a 21% increase compared to $8.35 billion in 2024 [3] - Instruments and accessories revenue for Q4 2025 increased by 17% to approximately $1.66 billion, up from $1.41 billion in Q4 2024, driven by an 18% growth in worldwide procedure volume [4] - Full year 2025 instruments and accessories revenue rose by 19% to approximately $6.02 billion, compared to $5.08 billion in 2024 [4] Procedure Volume - Q4 2025 da Vinci procedures increased by approximately 17% compared to Q4 2024, with a total of about 3,153,000 procedures performed in 2025, an 18% increase from approximately 2,683,000 in 2024 [5] - Growth in da Vinci procedure volume was largely due to an 18% increase in U.S. general surgery procedures and a 23% increase in procedures performed outside the U.S. [5] - Worldwide da Vinci procedures are expected to grow by approximately 13% to 15% in 2026 [5] System Placements - In Q4 2025, the company placed 532 da Vinci surgical systems, compared to 493 in Q4 2024, including 303 da Vinci 5 systems [6][8] - For the full year 2025, 1,721 da Vinci surgical systems were placed, an increase from 1,526 in 2024, with 870 being da Vinci 5 systems [9] Revenue Breakdown - Q4 2025 systems revenue was approximately $786 million, up from $655 million in Q4 2024, attributed to increased system placements and higher average selling prices [6][7] - Full year 2025 systems revenue reached approximately $2.47 billion, compared to $1.97 billion in 2024 [7] Company Outlook - CEO Dave Rosa expressed satisfaction with the company's performance, noting increased adoption and utilization of surgical platforms and over 3.1 million da Vinci procedures performed in 2025 [10] - The company is scheduled to present detailed financial results at the J.P. Morgan Healthcare Conference on January 14, 2026 [11]

Core Insights - Intuitive Surgical (ISRG) is positioning the da Vinci 5 system as a platform for expansion into new surgical specialties, particularly cardiac surgery, which could significantly broaden the company's total addressable market (TAM) in the long term [1][2][9] Company Developments - The da Vinci 5's enhanced features, including precision and digital capabilities, aim to make robotic surgery viable for cardiac patients who are not ideal candidates for traditional methods, indicating a medium-term R&D focus rather than immediate revenue generation [2][4] - ISRG has made regulatory progress in general surgery by submitting applications for nipple-sparing mastectomy, which aligns with the company's strengths and could facilitate quicker clinical adoption once approved [3][9] Competitive Landscape - The surgical robotics market is becoming more competitive, with Medtronic and Johnson & Johnson's MedTech unit achieving regulatory clearances that expand their robotic platforms into new clinical applications, highlighting a shift in market dynamics [5][6][7] - Medtronic received FDA clearance for its Hugo robotic-assisted surgery system for urologic procedures, marking its entry into a segment traditionally dominated by ISRG [6] - Johnson & Johnson's MONARCH Platform has received clearance for enhancements that improve access to lung nodules, showcasing innovation in the interventional pulmonology segment [7] Financial Performance - ISRG shares have increased by 11.3% over the past six months, outperforming the industry average increase of 9.1% [8] - The company trades at a forward price-to-earnings ratio of 60.66, which is above the industry average but lower than its five-year median of 71.52, indicating a mixed valuation perspective [10] - The Zacks Consensus Estimate for ISRG's 2026 earnings suggests an 11.1% increase compared to the previous year [11]

Company Overview - Stryker Corporation, based in Portage, Michigan, is a leading global medical technology company specializing in orthopaedics, MedSurg, and neurotechnology solutions, with a market cap of $135.7 billion [1] Earnings Expectations - Analysts anticipate Stryker to report a fiscal fourth-quarter profit of $4.39 per share on a diluted basis, reflecting a 9.5% increase from $4.01 per share in the same quarter last year [2] - For the full fiscal year, EPS is expected to be $13.56, an 11.2% increase from $12.19 in fiscal 2024, with further growth projected to $14.98 in fiscal 2026, representing a 10.5% year-over-year rise [3] Stock Performance - Stryker's stock has declined by 4.3% over the past year, underperforming the S&P 500 Index's 14.8% gains and the Health Care Select Sector SPDR Fund's 11.8% rise during the same period [4] Analyst Ratings - The consensus opinion on Stryker's stock is bullish, with a "Strong Buy" rating from 18 out of 27 analysts, while two suggest a "Moderate Buy" and seven give a "Hold" rating [6] - The average analyst price target for Stryker is $432.88, indicating a potential upside of 22% from current levels [6] Recent Developments - On December 19, Stryker's shares rose over 1% following an upgrade by Citizens JMP Securities from "Market Perform" to "Outperform," with a price target set at $440, reflecting confidence in the company's long-term growth outlook [5]

Earnings Report - Medtronic plc is set to release its second-quarter earnings results on November 18, with analysts expecting earnings of $1.31 per share, an increase from $1.26 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $8.86 billion, compared to $8.4 billion in the previous year [1] Clinical Study Announcement - On October 8, Medtronic announced the start of the Embrace Gynecology investigational device exemption (IDE) U.S. clinical study to evaluate the safety and effectiveness of its Hugo robotic-assisted surgery (RAS) system in gynecological procedures [2] - Following this announcement, Medtronic's shares rose by 0.4% to close at $96.28 [2] Analyst Ratings and Price Targets - JP Morgan analyst Robbie Marcus maintained a Neutral rating and raised the price target from $90 to $100 [8] - Truist Securities analyst Richard Newitter maintained a Hold rating and increased the price target from $96 to $103 [8] - Stifel analyst Rick Wise maintained a Hold rating and raised the price target from $90 to $105 [8] - Citigroup analyst Joanne Wuensch maintained a Buy rating and increased the price target from $101 to $112 [8] - Argus Research analyst David Toung maintained a Buy rating and raised the price target from $105 to $115 [8]